OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects

NCT05583474 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

204

Enrollment

INDUSTRY

Sponsor class

Conditions

Open Angle Glaucoma or Ocular Hypertension

Interventions

DRUG: OPC-1085EL
DRUG: 0.005% Latanoprost

Sponsor

Otsuka Beijing Research Institute